Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Agios Pharmaceuticals (AGIO) Return on Capital Employed (2016 - 2026)

Agios Pharmaceuticals (AGIO) has disclosed Return on Capital Employed for 14 consecutive years, with 0.4% as the latest value for Q1 2026.

  • For Q1 2026, Return on Capital Employed fell 12.0% year-over-year to 0.4%; the TTM value through Mar 2026 reached 0.4%, down 12.0%, while the annual FY2025 figure was 0.34%, 1.0% up from the prior year.
  • Return on Capital Employed hit 0.4% in Q1 2026 for Agios Pharmaceuticals, down from 0.37% in the prior quarter.
  • Across five years, Return on Capital Employed topped out at 0.26% in Q4 2024 and bottomed at 0.54% in Q2 2024.
  • Average Return on Capital Employed over 5 years is 0.36%, with a median of 0.35% recorded in 2024.
  • Year-over-year, Return on Capital Employed fell -19bps in 2024 and then grew 22bps in 2025.
  • Agios Pharmaceuticals' Return on Capital Employed stood at 0.34% in 2022, then dropped by -28bps to 0.43% in 2023, then soared by 40bps to 0.26% in 2024, then tumbled by -45bps to 0.37% in 2025, then dropped by -7bps to 0.4% in 2026.
  • According to Business Quant data, Return on Capital Employed over the past three periods came in at 0.4%, 0.37%, and 0.35% for Q1 2026, Q4 2025, and Q3 2025 respectively.